Clin2
NCT07720466Possibly a fitNot yet recruiting

Saliva and dental changes during weight-loss therapy

ObesityDental ErosionSaliva CollectionSaliva Altered

Part of Hormones & metabolism, Mouth & dental clinical trials.

This study looks at how a new weight-loss medication (semaglutide or tirzepatide) might affect your saliva and teeth. It follows people for 3 months to see any changes.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
40 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • Your BMI is 27 or higher.
  • Your doctor plans to start you on either semaglutide or tirzepatide for weight loss.
  • You have never taken a GLP-1 medication before.
  • You do not have Sjögren's syndrome, chronic kidney disease, or active orthodontic treatment.
  • You are willing to come for a check-up at the start and again after 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07770841Recruiting· Phase 3
Oral medication for weight loss study

This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.

Birmingham, Alabama
NCT07465965Recruiting· Phase 1
Weight loss study of semaglutide nasal spray in overweight or obese adults

This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.

Secaucus, New Jersey
NCT07627074Recruiting
Real-world weight loss study with semaglutide

This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.

Seattle, Washington
NCT07729332Not yet recruiting· Phase 4
Switching to oral weight-loss pills to prevent weight regain after stopping GLP-1 injections

This study tests whether switching to an oral weight-loss medication can help you keep off the weight you lost after stopping a GLP-1 injection like semaglutide or tirzepatide. You might qualify if you live in Massachusetts, are between 18 and 80, have a BMI of 30 or higher, lost at least 10% of your body weight on these injections, and are willing to be randomly assigned to a new treatment.

Boston, Massachusetts
NCT07323134Not yet recruiting
Semaglutide for obesity and gut health

This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.

NCT06825793Not yet recruiting
Semaglutide for weight loss in obesity

This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.